MedTrace Logo

A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly

NCT01906593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 536812

Last updated 2013-07-24

No results posted yet for this study

Summary

To monitor the safety of Beijing Tiantan Biological's influenza vaccine in elderly through Adverse Events Following Immunization Surveillance System of China.

The hypothesis is that there is no significant difference in the occurrence of adverse events among influenza vaccines manufactured by independent companies.

Conditions

Sponsors & Collaborators

  • Beijing Tiantan Biological Products Co., Ltd.

    collaborator INDUSTRY

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Jiang Wu, Master · Beijing Centers for Disease Prevention and Control, China

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01906593 on ClinicalTrials.gov